中国神经再生研究(英文版) ›› 2019, Vol. 14 ›› Issue (11): 1915-1916.doi: 10.4103/1673-5374.259615

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

间充质干细胞对疼痛治疗的影响

  

  • 出版日期:2019-11-15 发布日期:2019-11-15

Mesenchymal stem cells, implications for pain therapy

 Elena Trallori, Carla Ghelardini, Lorenzo Di Cesare Mannelli   

  1. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino - Neurofarba – Sezione di Farmacologia e Tossicologia, Universita degli Studi di Firenze, Florence, Italy
  • Online:2019-11-15 Published:2019-11-15
  • Contact: Lorenzo Di Cesare Mannelli, PhD, lorenzo.mannelli@unifi.it.

摘要:

orcid: 0000-0001-8374-4432 (Lorenzo Di Cesare Mannelli)

Abstract:

History and biology of mesenchymal stem cell (MSC): MSCs were firstly described around 1970s by Friedenstein and his collaborators as a subpopulation of colony forming, clonogenic, plastic adherent stromal bone marrow derived cells, with the capacity to regenerate other tissues . Caplan proposed that these mesenchymal cells were “stem” because of their ability to differentiate to any lineage of mesodermal cells. The richest sources of MSCs are bone marrow and adipose tissue, but they can also be isolated from synovial fluid, periosteum, fetal organs, placenta, umbilical cord blood and amniotic fluid.